Search results for:
bezlotoxumab
bezlotoxumab
- Restricted Miscellaneous Programs
- Restricted Restricted to ID & GI physicians in the outpatient setting following criteria for use
Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
Zinplava |
SOLUTION, INTRAVENOUS |
1,000 mg/40 mL (25 mg/mL) |
|
|
|
|
Last updated: May. 1, 2020
Cost: ewe
Restricted to use by GI and infectious disease in outpatient setting meeting criteria for use. Case review by pharmacist is planned for each patient; notify AMT pharmacist when drug is ordered. If ordered for an inpatient by approved prescribers, contact AMT pharmacist for review.
For other MDs, contact to discuss and interchange to IVIG in both inpatient and outpatient setting. INTERCHANGE IS NOT AUTOMATIC. Physician may decide on an alternative therapy.
Must be administered before the end of active anti-CDI therapy, and one or more of the below criteria must be met.
Criteria for use:
OR
2. At least 2 of the following risk factors for recurrence:
- Age >= 65
- Severe/fulminant* CDI
- Concomitant broad spectrum antibiotic utilization for another infection during treatment of CDI
- Immunocompromised (hematopoletic stem cell transplantation, use of immunosuppressive agents, active
malignancy, solid organ transplant)
*Definitions:
- Severe CDI: WBC count > 15 x 109/L OR creatinine > 1.5 mg/dL
- Fulminant CDI: Hypotension, schock, ileus, or megacolon
bezlotoxumab (Zinplava)
immune globulin intravenous (Gamunex)
Reviewed: 26 Sept 2017 (Zinplava), 28 April 2020